Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 881-885

  Riedinger, J M ^a   Bonnetain, F ^a   Basuyau, J P ^b   Eche, N ^c   Larbre, H ^d   Dalifard, I ^e   Wafflart, J ^f   Ricolleau, G ^g   Pichon, M F ^h  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d INSTITUT JEAN GODINOT   (France)

^e CENTRE PAUL PAPIN   (France)

^f INSTITUT BERGONIÉ   (France)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h CENTRE RENÉ HUGUENIN   (France)

Author keywords

CA 125; Chemotherapy; Ovarian cancer; Prognosis; Second look; Survival

Indexed keywords

CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; EPITHELIUM TUMOR; FEMALE; FOLLOW UP; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 34447303545     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl500     Document Type: Article

References (14)

1. Standards, Options et Recommandations. Tumeurs épithéliales malignes de l'ovaire. Paris, France: John Libbey Eurotext 1998.
2. Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life, and CA 125 nadir during induction chemotherapy are independent predictors of elpithelial ovarian cancer outcome. Results of a French multicentric study. Ann Oncol 2006; 17 (8): 1234-1238.
3. Sogaard CH, Lindegaard JC, Havsteen H et al. Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer. Gynecol Oncol 2005; 97 (2): 410-412.
4. Markman M, Federico M, Liu PY et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006; 103 (1): 195-198.
5. Rustin GJ, Gennings JN, Nelstrop AE et al. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 1989; 7 (11): 1667-1671.
6. Van der Burg ME, Lammes FB, van Putten WL, Stoter G. Ovarian cancer: The prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988; 30 (3): 307-312.
7. Sevelda P, Schemper M, Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161 (5): 1213-1216.
8. Mogensen O, Mogensen B, JakobsenA. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol 1990; 38 (2): 170-174.
9. Mogensen O, Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44 (3): 207-212.
10. Fisken J, Leonard RC, Stewart M et al. The prognostic value of early CA 125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993; 68 (1): 140-145.
11. Gadducci A, Zola P, Landoni F et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: Results of a multicentric Italian study. Gynecol Oncol 1995; 58 (1): 42-47.
12. Colakovic S, Lukic V, Mitrovic L et al. Prognostic value of CA 125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000; 15 (2): 147-152.
13. Ron IG, Inbar M, Gelernter I et al. Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand 1994; 73 (8): 658-662.
14. Redman CW, Blackledge GR, Kelly R et al. Early serum CA 125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990; 26 (5): 593-596.